Malignant function of nuclear factor-kappaB axis in prostate cancer: Molecular interactions and regulation by non-coding RNAs

Reyadh R Al-Rashidi,Sara Abdalrazzaq M Noraldeen,Ali Kamil Kareem,Aisha Kamal Mahmoud,Andrés Alexis Ramírez-Coronel,Acim Heri Iswanto,Rasha Fadhel Obaid,Abduladheem Turki Jalil,Yasser Fakri Mustafa,Noushin Nabavi,Yuzhuo Wang,Lin Wang,Wesam R. Kadhum

DOI: https://doi.org/10.1016/j.phrs.2023.106775

IF: 10.334

2023-04-01

Pharmacological Research

Abstract:Prostate carcinoma is a malignant situation that arises from genomic alterations in the prostate, leading to changes in tumorigenesis. The NF-κB pathway modulates various biological mechanisms, including inflammation and immune responses. Dysregulation of NF-κB promotes carcinogenesis, including increased proliferation, invasion, and therapy resistance. As an incurable disease globally, prostate cancer is a significant health concern, and research into genetic mutations and NF-κB function has the efficacy to facilitate the introduction of novel therapies. NF-κB upregulation is observed during prostate cancer progression, resulting in increased cell cycle progression and proliferation rates. Additionally, NF-κB endorses resistance to cell death and enhances the capacity for metastasis, particularly bone metastasis. Overexpression of NF-κB triggers chemoresistance and radio-resistance, and inhibition of NF-κB by anti-tumor compounds can reduce cancer progression. Interestingly, non-coding RNA transcripts can regulate NF-κB level and its nuclear transfer, offering a potential avenue for modulating prostate cancer progression.

pharmacology & pharmacy